All In Biotech

NDA 021688 · Amgen

Sensipar

Cinacalcet Hydrochloride · Oral

NovelPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Mar 8, 2004

Approved uses

4

Original approval plus efficacy supplements

Registered trials

73

23 Phase 3, 2 recruiting

FAERS reports

46,374

16,981 serious, 2,520 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 7, 2025.

Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) Hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. ( 1.3 ) 1.1 Secondary Hyperparathyroidism Sensipar is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis [see Clinical Studies ( 14.1 )]. Limitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis because of an increased risk of hypocalcemia [see Warnings and Precautions ( 5.1 )] . 1.2 Parathyroid Carcinoma Sensipar is indicated for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma [see Clinical Studies ( 14.2 )] . 1.3 Primary Hyperparathyroidism Sensipar is indicated for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy [see Clinical Studies ( 14.3 )] .

Mechanism: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, is a calcimimetic agent that directly lowers PTH levels by increasing the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SENSIPAR · CINACALCET HYDROCHLORIDE EQ 90MG BASE · TABLET, ORAL · Discontinued · TE AB
  • SENSIPAR · CINACALCET HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Discontinued · TE AB
  • SENSIPAR · CINACALCET HYDROCHLORIDE EQ 60MG BASE · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cinacalcet" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dose omission8,738
  • hospitalisation6,929
  • laboratory test abnormal4,222
  • off label use2,501
  • nausea2,285
  • intentional product misuse2,084
  • death1,834
  • malaise1,563
  • vomiting1,546
  • adverse drug reaction1,461
  • diarrhoea1,137
  • decreased appetite828

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004104
2005127
2006221
2007121
2008269
2009317
2010399
2011509
2012531
2013789
20141,009
20157,880
20167,587
201710,651
201812,675
2019773
2020388
2021329
2022446
2023413
2024422
2025287
2026127

Recalls

3 FDA enforcement reports for this application.

  • Jun 4, 2026 · Class II · Ongoing

    CGMP Deviations

  • Jun 4, 2026 · Class II · Ongoing

    CGMP Deviations

  • Jun 4, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sensipar (Cinacalcet HCl)

2024 spending

$1.3M

Beneficiaries

233

755 claims

Per beneficiary

$5,634

$33.04 per unit

View as table
YearSpending
2020$24,137,137
2021$6,666,170
2022$4,084,303
2023$2,727,699
2024$1,312,813

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 207 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.